Viking Therapeutics, Inc.
12340 El Camino Real, Suite 250
San Diego, CA 92130
January 3, 2018
VIA EDGAR
Securities and Exchange Commission
100 F Street, N.E.
Washington, D.C. 20549
|
Re: |
Viking Therapeutics, Inc. |
|
|
Registration Statement on Form S-1 |
|
|
Filed December 20, 2017 |
|
|
File No. 333-222202 |
Ladies and Gentlemen:
Reference is hereby made to the letter submitted via EDGAR by Viking Therapeutics, Inc. (the “Registrant”), dated December 29, 2017 (the “Acceleration Request”), which requested that the Registrant’s Registration Statement on Form S-1 (File No. 333-222202) be declared effective at 4:30 p.m., Eastern Time, on January 3, 2018, or as soon thereafter as practicable. The Registrant hereby requests withdrawal of the Acceleration Request.
Thank you for your assistance. Should you have any questions, please contact our outside counsel, Jeffrey T. Hartlin of Paul Hastings LLP, by telephone at (650) 320-1804 or by email at jeffhartlin@paulhastings.com.
|
|
Sincerely, |
|
|
|
|
|
|
|
VIKING THERAPEUTICS, INC. |
|
|
|
|
|
|
|
By: |
/s/ Brian Lian, Ph.D. |
|
|
|
Brian Lian, Ph.D. |
|
|
|
President and Chief Executive Officer |
|
|
|
|
cc:Jeffrey T. Hartlin, Esq. (Paul Hastings LLP)